Home > Maligne hematologie > Myeloïde ziekten > Acute myeloïde leukemie > AML (incl. APL) > Hovon 156

Printen

Versie:	1.0.0
Revisie:	30-09-2022
Type:	Studie
Status:	Gesloten voor inclusie
Ziektebeeld:	AML (incl. APL)
Behandellijn:	1ste lijn
Fase:	Fase 3
Leeftijd:	≥ 18
PI:	Dr. Ammatuna
TC:	Sanne van der Kooi
Titel:	A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy

Hovon 156

Studieprotocol

Hovon 156 Protocol

ICF

HO156 Main_ICF

A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy

Hovon 156

Hematologie Groningen